These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 23415433)
21. Niacin, an old drug with new perspectives for the management of dyslipidaemia. Benhalima K; Muls E Acta Clin Belg; 2010; 65(1):23-8. PubMed ID: 20373594 [TBL] [Abstract][Full Text] [Related]
22. Influence of the timing of low-dose aspirin on tolerability of prolonged-release nicotinic acid in patients at elevated cardiovascular risk. Alves JD; Steinhagen-Thiessen E; Darioli R; Hostalek U; Vogt A Curr Med Res Opin; 2008 Oct; 24(10):2815-20. PubMed ID: 18755055 [TBL] [Abstract][Full Text] [Related]
23. Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients. Bays HE; Maccubbin D; Meehan AG; Kuznetsova O; Mitchel YB; Paolini JF Clin Ther; 2009 Jan; 31(1):115-22. PubMed ID: 19243712 [TBL] [Abstract][Full Text] [Related]
24. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Maccubbin D; Bays HE; Olsson AG; Elinoff V; Elis A; Mitchel Y; Sirah W; Betteridge A; Reyes R; Yu Q; Kuznetsova O; Sisk CM; Pasternak RC; Paolini JF Int J Clin Pract; 2008 Dec; 62(12):1959-70. PubMed ID: 19166443 [TBL] [Abstract][Full Text] [Related]
25. Avoid no-flush niacin in favor of the prescription version. Follow certain steps to reduce the flushing effects of prescription niacin. Heart Advis; 2010 Nov; 13(11):5. PubMed ID: 22834056 [No Abstract] [Full Text] [Related]
26. Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis. Brinton EA; Kashyap ML; Vo AN; Thakkar RB; Jiang P; Padley RJ Am J Cardiovasc Drugs; 2011 Jun; 11(3):179-87. PubMed ID: 21619381 [TBL] [Abstract][Full Text] [Related]
27. Safety and tolerability of extended-release niacin with laropiprant. Yadav R; Kwok S; Ammori BJ; Issa B; Soran H Expert Opin Drug Saf; 2012 Jan; 11(1):151-9. PubMed ID: 22133050 [TBL] [Abstract][Full Text] [Related]
28. Flushing ASsessment Tool (FAST): psychometric properties of a new measure assessing flushing symptoms and clinical impact of niacin therapy. Kawata AK; Revicki DA; Thakkar R; Jiang P; Krause S; Davidson MH; Punzi HA; Padley RJ Clin Drug Investig; 2009; 29(4):215-29. PubMed ID: 19301936 [TBL] [Abstract][Full Text] [Related]
29. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Paolini JF; Mitchel YB; Reyes R; Kher U; Lai E; Watson DJ; Norquist JM; Meehan AG; Bays HE; Davidson M; Ballantyne CM Am J Cardiol; 2008 Mar; 101(5):625-30. PubMed ID: 18308010 [TBL] [Abstract][Full Text] [Related]
30. Niacin plus statin: powerful anti-cholesterol partnership. Use of the B vitamin niacin may help keep your cholesterol under control, but there are certain things you should know before starting therapy. Heart Advis; 2007 Jul; 10(7):9. PubMed ID: 17695658 [No Abstract] [Full Text] [Related]
31. Wax-matrix extended-release niacin vs inositol hexanicotinate: a comparison of wax-matrix, extended-release niacin to inositol hexanicotinate "no-flush" niacin in persons with mild to moderate dyslipidemia. Keenan JM J Clin Lipidol; 2013; 7(1):14-23. PubMed ID: 23351578 [TBL] [Abstract][Full Text] [Related]
32. Role of prostaglandin D2 and the autonomic nervous system in niacin-induced flushing. Parson HK; Harati H; Cooper D; Vinik AI J Diabetes; 2013 Mar; 5(1):59-67. PubMed ID: 22727040 [TBL] [Abstract][Full Text] [Related]
33. Niacin: its value in raising HDL cholesterol is being questioned. Heart Advis; 2011 Oct; 14(10):7. PubMed ID: 23019714 [No Abstract] [Full Text] [Related]
34. Niacin-a critical component to the management of atherosclerosis: contemporary management of dyslipidemia to prevent, reduce, or reverse atherosclerotic cardiovascular disease. Mason CM; Doneen AL J Cardiovasc Nurs; 2012; 27(4):303-16. PubMed ID: 21804401 [TBL] [Abstract][Full Text] [Related]
35. Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment. Oberwittler H; Baccara-Dinet M Int J Clin Pract; 2006 Jun; 60(6):707-15. PubMed ID: 16805757 [TBL] [Abstract][Full Text] [Related]